Alexithymia and its relationships with inflammatory response mediated by IL-1 family members

Journal of Biological Regulators and Homeostatic Agents

Volumn 31, Issue 1, 2017, Pages 21-28

  Conti, C ^a   Caraffa, A L ^b   Kritas, S K ^c   Ronconi, G ^d   Fulcheri, M ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Alexithymia; Cytokine; Inflammation; Interleukin; Psychological stress

Indexed keywords

CYTOKINE; INTERLEUKIN 1; ANTIINFLAMMATORY AGENT; IL33 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; INTERLEUKIN 33; INTERLEUKIN 6; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PSYCHOTROPIC AGENT;

ALEXITHYMIA; BIBLIOGRAPHIC DATABASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; GOOGLE SCHOLAR; HUMAN; INFLAMMATION; MAST CELL; MEDIATOR RELEASE; MEDICAL SUBJECT HEADINGS; MEDLINE; REVIEW; SCIENCEDIRECT; SCOPUS; AFFECTIVE SYMPTOMS; ANTAGONISTS AND INHIBITORS; BRAIN; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; QUALITY OF LIFE; SIGNAL TRANSDUCTION;

AFFECTIVE SYMPTOMS; ANTI-INFLAMMATORY AGENTS; BRAIN; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-33; INTERLEUKIN-6; MAST CELLS; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN ISOFORMS; PSYCHOTROPIC DRUGS; QUALITY OF LIFE; SIGNAL TRANSDUCTION;

EID: 85016228979     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Sifneos PE. The prevalence of 'alexithymic' characteristics in psychosomatic patients. Psychother Psychosom 1973;22:255-62.
2. De Berardis D, Campanella D, Serroni N, et al. The impact of alexithymia on anxiety disorders: a review of the literature. Curr Psychiatry Rev 2008;4:80-86.
3. De Berardis D, Conti C, Iasevoli F, et al. Alexithymia and its relationships with acute phase proteins and cytokine release: an updated review. J Biol Regul Homeost Agents 2014;28(4):795-9.
4. Todarello O, Casamassima A, Marinaccio M, La Pesa MW, Caradonna L, Valentino L, Marinaccio L. Alexithymia, immunity and cervical intraepithelial neoplasia: a pilot study. Psychother Psychosom 1994;61:199-204.
5. Todarello O, Casamassima A, Daniele S, et al. Alexithymia, immunity and cervical intraepithelial neoplasia: replication. Psychother Psychosom 1997;66:208-13.
6. Dewaraja R, Tanigawa T, Araki S, Nakata A, Kawamura N, Ago Y, Sasaki Y. Decreased cytotoxic lymphocyte counts in alexithymia. Psychother Psychosom 1997;66:83-86.
7. Guilbaud O, Corcos M, Hjalmarsson L, Loas G, Jeammet P. Is there a psychoneuroimmunological pathway between alexithymia and immunity? Immune and physiological correlates of alexithymia. Biomed Pharmacother 2003;57:292-95.
8. Guilbaud O, Curt F, Perrin C, et al. Decreased immune response in alexithymic women: a cross-sectional study. Biomed Pharmacother 2009;63:297-304.
9. Corcos M, Guilbaud O, Paterniti S, et al. Correlation between serum levels of interleukin-4 and alexithymia scores in healthy female subjects: preliminary findings. Psychoneuroendocrinology 2004;29:557-62.
10. Pedrosa GF, Nickel M, Ridout N, Schwarz MJ, Schoechlin C, Schmidmaier R. Alexithymia and interleukin variations in somatoform disorder. Neuroimmunomodulation 2007;14:235-42.
11. Uher T, Bob P. Cerebrospinal fluid IL-8 levels reflect symptoms of alexithymia in patients with non-inflammatory neurological disorders. Psychoneuroendocrinology 2011;36(8):1148-53.
12. Kiecolt-Glasser JK, McGuire L, Nobles TF, Laser R. Psychoneuroimmunology and psychosomatic medicine: back to the future. Psychosom Med 2002;64:15-28.
13. Zarković M, Ignjatović S, Dajak M, et al. Cortisol response to ACTH stimulation correlates with blood interleukin 6 concentration in healthy humans. Eur J Endocrinol 2008;159:649-52.
14. Marques AH, Silverman MN, Sternberg EM. Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics. Ann N Y Acad Sci 2009;1179:1-18.
15. Locatelli V, Bresciani E, Tamiazzo L, Torsello A. Central nervous system-acting drugs influencing hypothalamic-pituitary-adrenal axis function. Endocr Dev 2010;17:108-20.
16. Mandarelli G, Tarsitani L, Ippoliti F, Covotta F, Zerella MP, Mirigliani A, Biondi M. The relationship between alexithymia and circulating cytokine levels in sujects undergoing upper endoscopy. Neuroimmunomodulation 2011;18:37-44.
17. de Berardis D, Serroni N, Campanella D, et al. Alexithymia and its relationships with C-reactive protein and serum lipid levels among drug naïve adult outpatients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1982-86.
18. Honkalampi K, Lehto SM, Koivumaa-Honkanen H, Hintikka J, Niskanen L, Valkonen-Korhonen M, Viinamäki H. Alexithymia and tissue inflammation. Psychother Psychosom 2011;80(6):359-64.
19. Bossù P, Salani F, Cacciari C, et al. Disease outcome, alexithymia and depression are differently associated with serum IL-18 levels in acute stroke. Curr Neurovasc Res 2009;6(3):163-70.
20. Vadacca M, Bruni R, Cacciapaglia F, et al. Afeltra. Alexithymia and immunoendocrine parameters in patients affected by systemic lupus erythematosus and rheumatoid arthritis. Reumatismo 2008;60:50-56.
21. Temoshok LR, Waldstein SR, Wald RL, Garzino-Demo A, Synowski SJ, Sun L, Wiley JA. Type C coping, alexithymia, and heart rate reactivity are associated independently and differentially with specific immune mechanisms linked to HIV progression. Brain Behav Immun 2008;22(5):781-92.
22. Conti C, Mennitto C, Di Francesco G., Fraticelli F, Vitacolonna E, Fulcheri M. Clinical Characteristics of diabetes mellitus and suicide risk. Front Psychiatry 2017;8(1) DOI: 10.3389/fpsyt.2017.00040.
23. Tyrka AR, Parade SH, Valentine TR, Eslinger NM, Seifer R. Adversity in preschool-aged children: Effects on salivary interleukin-1β. Dev Psychopathol 2015;27(2):567-76.
24. Conti P, Ronconi G, Caraffa A, Lessiani G, Duraisamy K. IL-37 a new il-1 family member emerges as a key suppressor of asthma mediated by mast cells. Immunol Invest 2016;16:1-12.
25. Kempuraj D, Caraffa A, Ronconi G, Lessiani G, Conti P. Are mast cells important in diabetes? Pol J Pathol 2016;67(3):199-206.
26. Shaik-Dasthagirisaheb YB, Conti P. The role of mast cells in Alzheimer's disease. Adv Clin Exp Med 2016;25(4):781-87.
27. Theoharides TC, Stewart JM, Taracanova A, Conti P, Zouboulis CC. Neuroendocrinology of the skin. Rev Endocr Metab Disord 2016;17(3):287-94. Review.
28. Conti P, Kempuraj D. Important role of mast cells in multiple sclerosis. Mult Scler Relat Disord 2016;5:77-80. Review.
29. Kandere-Grzybowska K, Letourneau R, Kempuraj D, et al. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J Immunol 2003;171(9):4830-36.
30. Conti P, Shaik-Dasthagirisaeb Y. Atherosclerosis: a chronic inflammatory disease mediated by mast cells. Cent Eur J Immunol 2015;40(3):38086. Review.
31. Wenzel S. Mechanisms of severe asthma. Clin Exp Allergy 2003;33(12):1622-28.
32. Cavalli G, Koenders M, Kalabokis V, et al. Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatology (Oxford) 2016;55(12):2220-29.